Trials Sponsors Conditions Drugs Pricing

Conditions

Colorectal Cancer Metastatic Metastatic Melanoma Metastatic Non-Small Cell Lung Carcinoma

Outcome Measures

Primary Outcomes (3)

Quality of the biopsies
Percentage of frozen and FFPE core biopsies that are able to provide at least 1.5 μg of DNA of high quality suitable for molecular testing.
1 month
Technical failure rate.
Frequency of failures of each pathological and molecular tests.
1 month
Percentage of patients with results within the specified turnaround time
Percentage of patients for whom biopsy was performed within 10 working days from signature of the ICF and for whom all central laboratory results (pathology and molecular) will be available to the investigator within 15 working days from the time samples are received at the central laboratory (JBI).
1 month

Secondary Outcomes (1)

Feasibility of a tumor sequencing board.
2 months

Study Arms (1)

Sequencing of a metastatic lesion.

OTHER

Biopsy of a metastatic lesion followed by a targeted cancer gene screen.

Procedure: Biopsy of a metastatic lesion.

Interventions

Biopsy of a metastatic lesion.Procedure

Sequencing of a metastatic lesion.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Written informed consent for all study procedures according to local regulatory requirements prior to enrollment into the study.
Age ≥ 18 years.

Sponsors & Collaborators

Jules Bordet Institute
Otherlead

Study Sites (1)

Jules Bordet Institute

Brussels, 1000, Belgium

MeSH Terms

Conditions

MelanomaCarcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Study Officials

Philippe Aftimos, MD
Jules Bordet Insitute
PRINCIPAL INVESTIGATOR

Enrollment

35 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 23, 2013

First Posted

August 30, 2013

Study Start

December 2013

Date type not reported

This date has not been verified as actual or estimated.

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

Sequencing of a metastatic lesion.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

Sequencing of a metastatic lesion.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations